Cargando…
Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort
BACKGROUND: With the introduction of DNA-damaging therapies into standard of care cancer treatment, there is a growing need for predictive diagnostics assessing homologous recombination deficiency (HRD) status across tumor types. Following the strong clinical evidence for the utility of DNA-sequenci...
Autores principales: | Leibowitz, Benjamin D., Dougherty, Bonnie V., Bell, Joshua S. K., Kapilivsky, Joshuah, Michuda, Jackson, Sedgewick, Andrew J., Munson, Wesley A., Chandra, Tushar A., Dry, Jonathan R., Beaubier, Nike, Igartua, Catherine, Taxter, Timothy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148513/ https://www.ncbi.nlm.nih.gov/pubmed/35643464 http://dx.doi.org/10.1186/s12885-022-09669-z |
Ejemplares similares
-
Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin
por: Michuda, Jackson, et al.
Publicado: (2023) -
Pan-cancer landscape of homologous recombination deficiency
por: Nguyen, Luan, et al.
Publicado: (2020) -
Homologous Recombination Deficiency: Concepts, Definitions, and Assays
por: Stewart, Mark D, et al.
Publicado: (2022) -
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
por: Beaubier, Nike, et al.
Publicado: (2019) -
Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images
por: Sha, Lingdao, et al.
Publicado: (2019)